AR092325A1 - Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit - Google Patents
Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kitInfo
- Publication number
- AR092325A1 AR092325A1 ARP130101868A ARP130101868A AR092325A1 AR 092325 A1 AR092325 A1 AR 092325A1 AR P130101868 A ARP130101868 A AR P130101868A AR P130101868 A ARP130101868 A AR P130101868A AR 092325 A1 AR092325 A1 AR 092325A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- kit
- formulations containing
- containing anti
- dll4 antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
Reivindicación 1: Una formulación farmacéutica que comprende: (i) un anticuerpo que se une específicamente a ligando tipo d humano 4 (Dll4); (ii) un amortiguador a pH de 6,0 ± 0,5; (iii) un cosolvente orgánico; y (iv) dos estabilizadores térmicos. Reivindicación 2: La formulación farmacéutica de acuerdo con la reivindicación 1, en donde el anticuerpo comprende una HCDR1 de SEC ID Nº 2, una HCDR2 de SEC ID Nº 3, una HCDR3 de SEC ID Nº 4, una LCDR1 de SEC ID Nº 6, una LCDR2 de SEC ID Nº 7 y una LCDR3 de SEC ID Nº 8. Reivindicación 3: La formulación farmacéutica de acuerdo con la reivindicación 1 o la reivindicación 2, en donde el anticuerpo comprende una HCVD de SEC ID Nº 1 y una LCVD de SEC ID Nº 5.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261653478P | 2012-05-31 | 2012-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR092325A1 true AR092325A1 (es) | 2015-04-15 |
Family
ID=48670784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101868A AR092325A1 (es) | 2012-05-31 | 2013-05-29 | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US9675692B2 (es) |
| EP (1) | EP2854849B1 (es) |
| JP (1) | JP6144758B2 (es) |
| KR (1) | KR20150033615A (es) |
| CN (1) | CN104349791A (es) |
| AR (1) | AR092325A1 (es) |
| AU (1) | AU2013267301B2 (es) |
| BR (1) | BR112014028997A2 (es) |
| CA (1) | CA2872275C (es) |
| CL (1) | CL2014003237A1 (es) |
| CO (1) | CO7151478A2 (es) |
| DK (1) | DK2854849T3 (es) |
| EA (1) | EA029779B1 (es) |
| ES (1) | ES2668900T3 (es) |
| HK (1) | HK1207305A1 (es) |
| IL (1) | IL235468A0 (es) |
| LT (1) | LT2854849T (es) |
| MA (1) | MA37645B1 (es) |
| MX (1) | MX357146B (es) |
| NO (1) | NO2887943T3 (es) |
| NZ (1) | NZ702288A (es) |
| PH (1) | PH12014502429B1 (es) |
| PL (1) | PL2854849T3 (es) |
| PT (1) | PT2854849T (es) |
| SG (1) | SG11201407171XA (es) |
| SI (1) | SI2854849T1 (es) |
| TW (1) | TWI609696B (es) |
| UY (1) | UY34842A (es) |
| WO (1) | WO2013181486A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2488204B1 (en) | 2009-10-16 | 2016-04-06 | Oncomed Pharmaceuticals, Inc. | Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents |
| RS63965B1 (sr) | 2011-09-23 | 2023-03-31 | Mereo Biopharma 5 Inc | Vegf/dll4 vеzujući agensi i njihova upotreba |
| JP6827415B2 (ja) | 2014-10-31 | 2021-02-10 | メレオ バイオファーマ ５ インコーポレイテッド | 疾患の処置のための併用療法 |
| JP6781508B2 (ja) * | 2014-11-18 | 2020-11-04 | 塩野義製薬株式会社 | 安定化されたペプチド組成物 |
| EP3353204B1 (en) | 2015-09-23 | 2023-10-18 | Mereo BioPharma 5, Inc. | Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer |
| JP7570234B2 (ja) * | 2018-04-16 | 2024-10-21 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 熱安定性を改善するためのタンパク質製剤のための添加剤 |
| PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
| WO2022010988A1 (en) * | 2020-07-08 | 2022-01-13 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ctla-4 antibodies |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
| US5016784A (en) | 1990-02-15 | 1991-05-21 | Dexus Research Inc. | Applicator for highly reactive materials |
| WO1993000807A1 (en) | 1991-07-03 | 1993-01-21 | Cryolife, Inc. | Method for stabilization of biomaterials |
| JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
| WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
| US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| IL133220A0 (en) | 1997-06-13 | 2001-03-19 | Genentech Inc | Stabilized antibody formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
| US7001892B1 (en) | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| EP1314437B1 (en) | 2000-08-11 | 2014-06-25 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing preparations |
| US6875432B2 (en) | 2000-10-12 | 2005-04-05 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| WO2003009817A2 (en) | 2001-07-25 | 2003-02-06 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| JP3792698B2 (ja) | 2002-02-14 | 2006-07-05 | 中外製薬株式会社 | 抗体含有溶液製剤 |
| US20040191243A1 (en) | 2002-12-13 | 2004-09-30 | Bei Chen | System and method for stabilizing antibodies with histidine |
| BRPI0403964B8 (pt) | 2003-04-04 | 2021-05-25 | Genentech Inc | formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige |
| WO2005072772A1 (en) | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| SI2586459T1 (sl) | 2005-03-25 | 2017-10-30 | Regeneron Pharmaceuticals, Inc. | Formulacije antagonistov VEGF |
| EA012801B1 (ru) | 2005-06-14 | 2009-12-30 | Эмджен Инк. | Самобуферирующиеся композиции белков |
| AU2007261536B2 (en) | 2006-06-16 | 2012-02-16 | Regeneron Pharmaceuticals, Inc. | VEGF antagonist formulations suitable for intravitreal administration |
| WO2008049897A1 (en) | 2006-10-27 | 2008-05-02 | Ablynx N.V. | Intranasal delivery of polypeptides and proteins |
| NO347649B1 (no) * | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| AU2010221156A1 (en) | 2009-03-06 | 2011-09-22 | Genentech, Inc. | Antibody formulation |
| EP2488204B1 (en) * | 2009-10-16 | 2016-04-06 | Oncomed Pharmaceuticals, Inc. | Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents |
| MX2012005863A (es) | 2009-11-20 | 2013-01-18 | Centro Inmunologia Molecular | Formulaciones de anticuerpos. |
| CA2791631A1 (en) * | 2010-03-02 | 2011-09-09 | Abbvie Inc. | Therapeutic dll4 binding proteins |
| EA028945B1 (ru) * | 2010-10-06 | 2018-01-31 | Ридженерон Фармасьютикалз, Инк. | СТАБИЛЬНЫЕ ЖИДКИЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТИТЕЛА К АЛЬФА РЕЦЕПТОРУ ЧЕЛОВЕЧЕСКОГО ИНТЕРЛЕЙКИНА-4 (hIL-4Rα) |
-
2013
- 2013-05-29 AR ARP130101868A patent/AR092325A1/es unknown
- 2013-05-30 TW TW102119047A patent/TWI609696B/zh not_active IP Right Cessation
- 2013-05-31 CA CA2872275A patent/CA2872275C/en active Active
- 2013-05-31 DK DK13730702.1T patent/DK2854849T3/en active
- 2013-05-31 UY UY0001034842A patent/UY34842A/es unknown
- 2013-05-31 ES ES13730702.1T patent/ES2668900T3/es active Active
- 2013-05-31 AU AU2013267301A patent/AU2013267301B2/en active Active
- 2013-05-31 NZ NZ702288A patent/NZ702288A/en not_active IP Right Cessation
- 2013-05-31 SG SG11201407171XA patent/SG11201407171XA/en unknown
- 2013-05-31 JP JP2015515218A patent/JP6144758B2/ja active Active
- 2013-05-31 LT LTEP13730702.1T patent/LT2854849T/lt unknown
- 2013-05-31 EP EP13730702.1A patent/EP2854849B1/en active Active
- 2013-05-31 CN CN201380028578.1A patent/CN104349791A/zh active Pending
- 2013-05-31 WO PCT/US2013/043516 patent/WO2013181486A1/en active Application Filing
- 2013-05-31 EA EA201492186A patent/EA029779B1/ru not_active IP Right Cessation
- 2013-05-31 PL PL13730702T patent/PL2854849T3/pl unknown
- 2013-05-31 KR KR1020147035879A patent/KR20150033615A/ko not_active Application Discontinuation
- 2013-05-31 MA MA37645A patent/MA37645B1/fr unknown
- 2013-05-31 US US13/906,479 patent/US9675692B2/en active Active
- 2013-05-31 PT PT137307021T patent/PT2854849T/pt unknown
- 2013-05-31 MX MX2014014363A patent/MX357146B/es active IP Right Grant
- 2013-05-31 SI SI201330979T patent/SI2854849T1/en unknown
- 2013-05-31 BR BR112014028997A patent/BR112014028997A2/pt not_active IP Right Cessation
- 2013-08-23 NO NO13831626A patent/NO2887943T3/no unknown
-
2014
- 2014-10-29 PH PH12014502429A patent/PH12014502429B1/en unknown
- 2014-11-03 IL IL235468A patent/IL235468A0/en unknown
- 2014-11-27 CL CL2014003237A patent/CL2014003237A1/es unknown
- 2014-12-23 CO CO14281503A patent/CO7151478A2/es unknown
-
2015
- 2015-08-18 HK HK15108004.0A patent/HK1207305A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR092325A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit | |
| PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
| NZ630885A (en) | Antibody formulation | |
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
| PE20170903A1 (es) | Conjugados de farmacos con anticuerpos anti-cdh6 | |
| PE20130226A1 (es) | Anticuerpos hacia gdf8 humano | |
| PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| NZ627859A (en) | Stabilized formulations containing anti-ang2 antibodies | |
| PE20181090A1 (es) | Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38 | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| AR071891A1 (es) | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| PE20091261A1 (es) | Anticuerpos anti-hepcidina | |
| NZ731735A (en) | Anti-pd-1 antibodies and methods of use thereof | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| PE20170916A1 (es) | Composiciones y metodos para anticuerpos dirigidos a bmp6 | |
| NZ719036A (en) | Anti-pdl1 antibody formulations | |
| PE20142170A1 (es) | Anticuerpos frente a los ligandos del receptor b1 de bradicinina | |
| NZ729158A (en) | Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use | |
| AR081434A1 (es) | Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo | |
| PE20141147A1 (es) | Anticuerpos a pcsk9 y usos de los mismos | |
| PE20141706A1 (es) | Anticuerpos de union a trombina y usos del mismo | |
| NI200900022A (es) | Anticuerpo especifico de prlr y usos del mismo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |